Telix Adds FAP-Targeting Theranostic Candidates to Pipeline
Filed with ASX · · 3 pages · English
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- CMS payment improvement decision for radiopharma diagnostics
- FDA accepts NDA and grants priority review for Pixclara
- Telix Files Form 20-F Registration Statement for Nasdaq ADS
- Telix Q3 2024 Revenue and Business Update
- Telix to Acquire RLS for US Manufacturing and Distribution
Later from Telix Pharmaceuticals
- Presentation to Accompany FAP-Targeting Acquisition
- TLX to Acquire Next-Gen Therapeutics and Biologics Platform
- Presentation to Accompany Biologics Platform Acquisition
- Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
- Telix JP Morgan Healthcare Conference 2025 Presentation
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals